CME Information
Activity Title |
Patient Who Develops de novo Features of ILD After a COVID-19 Infection |
Topic |
Pulmonary Disease |
Accreditation Type |
AMA PRA Category 1 Credit(s)™/ABIM MOC Part II/Pending approval for nursing credit |
Release Date |
July 16, 2021 |
Expiration Date |
July 15, 2022 |
Estimated Time to Complete Activity |
15 minutes |
LEARNING OBJECTIVE
Upon completion of the activity, participants should be able to:
- Evaluate non-PF-ILD COVID-19 patients for fibrotic changes in the lungs after recovery
PLANNING COMMITTEE
Joe Barney, MD, MSPH, FCCP
Associate Professor of Medicine, University of Alabama at Birmingham, Birmingham, AL
Amy Hajari Case, MD
Director of the Advanced Lung Disease Program and Medical Director of Pulmonary and Critical Care Research, Piedmont Healthcare, Austell, GA
Thank you to Dr. Case for her additional contributions to this enduring module
Sonye Danoff, MD, PhD
Associate Professor of Medicine, Co-Director of ILD Clinic, Johns Hopkins, Baltimore, MD
Vikramjit Khangoora, MD
Pulmonary and Critical Care Medicine Faculty,
Advanced Lung Disease and Lung Transplant Program,
Inova Fairfax Hospital, Falls Church, VA
Ganesh Raghu, MD
Professor, Director ILD PF Program, University of Washington, Seattle, WA
Elizabeth Volkmann, MD, MS
Director, UCLA Scleroderma Center, Co-Director UCLA CTD-ILD Program, University of California, Los Angeles, CA
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™, nursing credits, or a certificate of participation—your CME/CE certificate will be available for download
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
ACCREDITED PROVIDER
This activity is provided by The France Foundation.
TARGET AUDIENCE
This activity is intended for pulmonologists, rheumatologists, dermatologists, primary care providers, respiratory nurses/nurse practitioners/physician assistants, and other health care providers who may be involved in the management of patients with ILD.
STATEMENT OF NEED
There is a significant unmet need for better management of PF-ILD patients, and drug indications have been approved. Given the devastating effects PF-ILD has on patient mortality and quality of life and the frequent delays in diagnosis, outdated guidelines, and new approved medications, physicians must be up to date with new information as it emerges on PF-ILD.
ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit
Nurses: This activity has been submitted to Montana Nurses Association for approval to award contact hours. Montana Nurses Association is accredited with distinction as an approver of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
Faculty Disclosures
The faculty listed below report that they have no relevant financial relationships to disclose:
- Joseph Barney, MD, MSPH, FCCP
- Vikramjit Khangoora, MD
The faculty listed below report that they have relevant financial relationships to disclose:
- Amy Hajari Case, MD, has served on a speaker’s bureau for Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech. She has done contract research for Boehringer Ingelheim Pharmaceuticals, Inc., Bellerophon, Galapagos, Gilead, Kadmon, Kinevant, and United Therapeutics. She has an employment relationship with the Pulmonary Fibrosis Foundation.
- Sonya Danoff, MD, PhD, has done non-CE consulting for Boehringer Ingelheim Pharmaceuticals, Inc. and Lupin. She has done contract research for Boehringer Ingelheim Pharmaceuticals, Inc., Genentech/Roche and BMS. She has an employment relationship with the Pulmonary Fibrosis Foundation.
- Ganesh Raghu, MD, has done consulting for Avalyn, Boehringer Ingelheim Pharmaceuticals, Inc., BMS, Biogen, Bellerophon Fibrogen, Nitto, Lupin, Roche-Genentech, United Therapeutics, Veracyte, and Zambon
- Elizabeth Volkmann, MD, MS, has done non-CE consulting for Boehringer Ingelheim Pharmaceuticals, Inc. and Forbius
DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.
CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.